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A System Dynamics Model of Data-Driven Precision Medicine Ecosystem 
Tomi Sorasalmi, Jaakko Lähteenmäki, Peter Ylén 
VTT Technical Research Centre of Finland 
Abstract 
Biobanking and secondary use of healthcare data enable considerable improvement to healthcare 
through personalized medicine including innovative therapies, pharmaceuticals, medical technology, 
and healthcare processes tailored for the needs of individuals. The data-driven precision medicine 
ecosystem requires contributions from a large variety of stakeholders as well as public investments to 
boost ecosystem growth. This paper introduces a system dynamics model describing mechanisms for 
biobank data and biosample accumulation and the related impact to pharmaceutical R&D projects.  
The preliminary simulation results reflect the important role of public funding of the infrastructure 
needed for biobank and register data exploitation as well as setting up services to attract more 
donors. Large public-private precision medicine projects, such as the FinnGen project are in a key role. 
Further work is needed to improve the ecosystem model precision especially in taking into account 
the differences between pharmaceutical R&D projects and their data exploitation needs.  
Keywords: biobank, system dynamics, healthcare data, precision medicine, business ecosystem, 
innovation ecosystem 
1 Introduction 
Biobanking and secondary use of healthcare data enable considerable improvement to healthcare 
through personalized medicine including innovative therapies, pharmaceuticals, medical technology, 
and healthcare processes tailored for the needs of individuals. Secondary use of healthcare data 
enables data to be used for monitoring the quality of provided services, in the development of new 
services or products and for scientific research. Secondary use is permitted under certain conditions 
by the existing privacy legislation, in particular, the General Data Protection Regulation (GDPR). 
Additionally, specific legislation addressing secondary use of health data and biobanking has been 
implemented in in Finland1,2.  
Based on the legislation on secondary use (2019) the new data permit authority (Findata) was 
established, with services gradually starting during year 2020.  Based on the Biobank Act (2013) ten 
biobanks have been established and are operating in Finland at the moment: six biobanks covering 
the university hospital districts and four national biobanks3. An important step towards centralised 
biobank services was the opening of the Fingenious service of the Finnish Biobank (FinBB).  
Fingenious enables feasibility and access requests to be done for all hospital biobanks and the THL 
biobank via one joint service.  
The new centralized services together with the supporting legislation are targeted to facilitate more 
efficient and secure use of data of the various local registers, biobanks, centralized Kanta services as 
                                                          
1 Biobank Act, https://www.finlex.fi/fi/laki/kaannokset/2012/en20120688.pdf 
2 Act on the secondary use of health and social data, https://stm.fi/en/secondary-use-of-health-and-social-data 
3 http://www.bbmri.fi/bbmri-network/finnish-biobanks/ 
well as the national statistical registers. The services are intended to benefit both the academic 
community and the industry. Full exploitation of data will require efficient co-operation between all 
stakeholders including the centralized services (Findata and FinBB), health and social care register 
controllers, the industry and the providers of research services. The industrial stakeholders include 
large pharmaceutical and diagnostics companies, food industry, medical device manufacturers and a 
wide spectrum of SME companies offering research, diagnostics, data management, bioinformatics 
and software services.  
The data-driven precision medicine ecosystem is expected to lead to remarkable economic benefits 
through new products and business opportunities. However, considerable public investments are 
needed, e.g. to establish the required infrastructure (data/samples, biobank processes, data 
application evaluation processes, etc.), to accelerate the R&D of ecosystem companies and to 
support related academic research. For decision-makers an important question is how to support the 
data-driven precision medicine ecosystem growth to achieve maximum benefit for the society.   
Figure 1 shows the conceptual high-level data-driven precision medicine ecosystem model as 
identified in the PreMed project (Lähteenmäki et al., 2020).  The model is especially targeted to 
describe the effects of public investments in the ecosystem. The primary outcome measure is the 
volume of projects - referred as real world data (RWD) projects (Bartlett et al., 2019) -  which are 
based on exploitation of data obtained from biobanks and national registers. The model assumes 
that willingness of the industry to initiate and execute new RWD projects depends mainly on the 
availability and value of data, results from past projects (both academic and industry driven) and 
related services needed in the analysis of data and biosamples (blood or tissue samples).       
 
Figure 1. Conceptual high-level ecosystem model showing main stakeholder groups and dependences affecting the 
exploitation of health data.  
The conceptual ecosystem model includes the relevant ecosystem stakeholders and their main 
connections. The model takes into account the main mechanisms for companies to benefit from 
secondary use of data: (1) direct use of data by carrying out in-house studies, (2) using external 
research services, and (3) adopting results from academic studies. In all cases, the use of data 
(and/or biosamples) involves fees to be paid and if sample analytics have been carried out in a 
biobank study, the results need to be returned to the biobank in order to enrich the value of the 
sample. The ecosystem includes various types of companies either in the role of using data in their 
R&D activities or in providing support services to facilitate the use of data and samples.  Centers of 
excellence in Figure 1 refer to the Finnish national centers under development in the areas of cancer, 
neurological disorders, pharmaceutical development and genomics. These organisations are being 
set up with the objective of promoting research and public-private co-operation in the respective 
areas.  
The conceptual ecosystem model depicted in Figure 1 has been implemented as a simulation model, 
which enables the analysis of various ecosystem evolution paths affected by different public 
investment strategies. The model enables the effect of investments to biobanks, Findata, academic 
research, and support services to be estimated (centers of excellence have been omitted from this 
version of the model). The simulation model is expected to be valuable for public entities and 
authorities in providing support for the selection of financing strategies to boost ecosystem growth. 
Also other stakeholders can find the simulation model useful in increasing the understanding of the 
ecosystem dynamics. 
The approach presented in this paper to model and simulate the evolution of the data-driven 
precision medicine ecosystem from the perspective of biobanks is novel. Biobanking has been 
studied mainly from legal and social perspectives, especially concerning the privacy issues regarding 
healthcare data (Burgess, O’Doherty and Secko, 2008) and (Townend, 2016).  Also, the Finnish 
biobank ecosystem has been studied from a data privacy viewpoint (Soini, 2016). Ecosystem 
simulation approach, especially system dynamics, has been used to model different kinds of 
innovation and business ecosystems, for example, in the context of technological innovation 
ecosystems (Walrave and Raven, 2016; Raven and Walrave, 2018) and in the context of digital service 
platforms (Ruutu, Casey and Kotovirta, 2017). To our knowledge, ecosystem simulation modelling 
perspective has not been applied to biobanking. 
In this paper we present a model of a data-driven precision medicine ecosystem and initial simulation 
results of the different future development scenarios of the ecosystem. The aim of the paper is 1) to 
visualize the interconnections of the different stakeholders of the ecosystem, 2) to study the effects 
of different sectors of the system on the whole system, 3) to study the long term effects of public 
investment policies, and 4) study which factors support and which restrict the development of data-
driven precision medicine ecosystem. The effects are measured by the number of industrial R&D 
projects based on exploitation of health data and biosample resources.    
2 Modelling the data-driven precision medicine ecosystem 
2.1 Model overview 
The ecosystem simulation model was constructed based on available open material and information 
received from representatives of biobanks, healthcare providers, authorities and industry. As already 
shown in Figure 1, exploitation of health data involves a wide range of companies and public 
organizations forming a complex system. A simplified simulation model of the ecosystem is 
presented in Figure 2. The ecosystem model consists of five sectors that interact with each other. The 
sectors are (a more detailed description of each of the sectors is presented in section 2.2): 
1. Biobanks:   
o Donors and donor services: Donors describes the number of persons who have given 
a biobank consent for the use of their health care data and samples. Donor services 
describe the services set up for collecting consents from potential biobank donors.  
Donor services include also online services for giving and managing the biobank 
consents and can also be seen as a way of providing information for the donors 
where their samples and data have been used. It is expected that availability of 
different kinds of donor services especially in the context of healthcare services will 
increase interest towards giving biobank consents. 
o Biobank samples and data: Describes the amount of samples and data collected 
from the biobank donors under biobank consent as well as the processes for 
collecting samples and generating data.  
2. Pharmaceutical R&D: Describes the research and development activities specifically 
exploiting health care data and conducted by the pharmaceutical companies. Real world data 
(RWD) projects are typical examples of such pharmaceutical R&D. The main impacts of the 
pharmaceutical R&D projects on other parts of the ecosystem are as follows: 1) R&D projects 
provide service fees to biobanks and Findata, 2) R&D projects return the sample-level 
analytics results back to biobanks, thus causing sample enriching, and 3) R&D projects use 
external services from companies and thus enable the operations of support services. 
3. Findata1:  Findata provides services for accessing healthcare data for secondary use. Findata 
focuses on providing availability and data permit services for national register data. 
Deployment of Findata services is expected to shorten times for accessing register data and 
thereby increase industrial interest towards data exploitation. Currently, Findata is not 
covering biobank resources, which need to be applied separately from the biobanks. 
o Register data: Describes the amount of register data available. Register data includes 
patient record data (use of healthcare services, diagnoses, procedures, medication, 
laboratory, etc.) in local registries and in the centralized Kanta archive as well as data 
collected in national registers for quality monitoring, statistics and research.  
4. Support services: Describes the services which the pharmaceutical companies need in their 
R&D projects and which they are not able (or willing) to do themselves. These services may 
include different kinds of data analytics, laboratory analyses, software development, etc. 
Support services consist mainly of private sector companies, but also include the services 
provided by research centers and other publicly funded organizations. The availability of 
support services is expected to affect positively in the pharmaceutical companies' interest 
and ability to conduct R&D projects.  
5. Academic research: Describes academic research specifically based on the resources of 
biobanks and health care registers.  





























































































































































































































































2.2 Model description 
2.2.1 Biobank consents 
Figure 3 represents the part of the model that describes the donor services and how biobank consents are 
collected. Loop B1 causes the number of biobank consents to saturate as the number of biobank consents 
increase and as the number of potential biobank donors decreases when consents are given and thus the 
likelihood of finding new biobank donors decreases. The availability of donor services counter-balances the 
effect of this loop to some extend as long as donor services are developing, but eventually B1 will cause 
decrease in signing rate.  
 
Figure 3: Biobank consent dynamics 
Biobank consents has its own dynamics but is not connected to the other parts of the model by feedback 
loops, that is, nothing in the other parts of the model is feeding back to biobank consents. The number of 
consents is mainly driven by the personal choice of individuals which can be positively influenced by useful 
donor services.  
2.2.2 Biobanks 
The biobank section of the model describes biobank operations from the point of view of generating 
sample and data resources. It does not cover other operational and financial mechanisms of the biobanks.    
Figure 4 presents the model part describing the biobank sample and data generation. Samples are 
generated along with signed consents. This generates a sample for both Samples for genotyping and 
Samples in biobanks stocks. Genotyped data in biobanks is generated by direct genotyping funded 
externally or by enriching samples. Data in biobanks is only generated by enriching. 
Value of data and sample resources for secondary use is a combination of the following data resources: 
Data and samples in biobanks and Register data. Also, the Data integration capability affects the amount of 
data available (described in 2.2.4). 
The variable Samples in biobanks is assumed to be an inexhaustible source of data, as one sample (blood or 
tissue) can be used several times for different types of analytics.  The variable Samples for genotyping on 











































Figure 4: Biobank sample and data generation 
Data enrichment is an important feedback from the pharmaceutical R&D and academic research back to 
biobanks. This feedback is described by loops R1 and R2 in Figure 2. Data enriching, as described by the 
model, is the only process that is producing data from Samples in biobanks. When samples are used in R&D 
projects, according to the Material Transfer Agreements (MTA) the enriched data has to be returned back 
to the biobanks. This in turn increases the amount of available data resources for further use and thereby 
attracts new projects. 
It should be noted that Samples in biobanks is not directly affecting the enriching data for Data in biobanks. 
This effect comes through projects using the data and then enriching it. However, we have indicated the 
link by dashed line that the data is produced from the samples. 
2.2.3 Pharmaceutical R&D Projects and budget growth 
A key objective of the model is to determine what affects the budget available for pharmaceutical R&D 
project and thus the project starts. Figure 5 presents the variables affecting R&D budget and R&D project 
proposals.  
 
The main effect comes from the Value of data and sample resources for secondary use defined in Section  
2.2.2. We have assumed that pharmaceutical R&D is positively affected by the value of health data 
available for use (affected by the richness of data and samples as well as the possibility to merge data from 
different sources). We have not taken into consideration the possible effects of the number of donors 
relative to available data, or the variability of the resources (e.g. blood vs tissue samples), but aggregated 
the effect of these in the single variable Value of data and sample resources for secondary use. We have 
given different weights to samples and data extracted from the samples, as the data is in more accessible 
format. Also, genotyped data is given different weight from other data. 
 
The budget reserved by pharmaceutical companies for R&D has a major impact on the project proposals. 
When the number of R&D projects increases the budget becomes a limiting factor for the projects as 











































































described by loop R3. The variable Growth rate of R&D budget is determined by the variable Attractiveness 
of healthcare data for R&D. This loop accounts for the long term growth of the pharmaceutical companies' 
R&D project volume. 
  
Figure 5: Pharmaceutical R&D 
Support service availability has mainly a negative impact: incapability of the support services to match the 
requirements of the ongoing R&D projects reduces companies´ willingness to initiate new R&D project 
proposals. The pharmaceutical companies may not be able to carry out their intended R&D projects 
without appropriate support services. The effect of support services is discussed in more detail in section 
2.2.5. The effects of Findata come through the improved application process reducing the needed effort 
and delay in accessing data as described in section 2.2.4. We have assumed that the application process 
delay has an effect on how interested the pharmaceutical companies are to initiate new projects. 
2.2.4 Findata 
Findata is an important stakeholder in promoting the development of the ecosystem. When fully 
operational, Findata will affect the number of R&D projects mainly in two different ways, shown in Figure 6. 
First, the evaluation of healthcare data applications will be done in one place (“one-stop-shop”), which is 
supposed to decrease the evaluation time and labour intensity of the data application process significantly. 
Secondly, Findata is expected to allow better opportunities for integrating data from various registers. 
 
Figure 6: Findata 
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The financial effect of service fees collected by Findata is not expected to be large. Findata is a public entity 
supported by the state budget and not intended to create profit. Therefore the importance of the loops R4 
and R5 is relatively weak. However, there is a high demand by pharmaceutical companies and research 
organisations for Findata services, thus motivating and driving its development. This makes public 
investment in Findata an important decision point in the ecosystem. 
Loop R4 describes the possibilities and efficiency of integration of different data sources. The ability to 
integrate data from various sources, namely from national registers, healthcare service providers' registers 
and from biobanks, enhances the utility of the data. Data integration capability therefore effect on the 
value of available data resources for secondary use. The value of data in turn affects the interest of 
pharmaceutical companies to utilize the data.  
Loop R5 describes the delay of Findata's processes affecting the waiting time for data access. Public 
investments to Findata are used to streamline the data application process and to reduce the application 
evaluation time.  
2.2.5 Support services 
The structure of support services is presented in Figure 7. Loop B2 describes how the demand and supply of 
support services affects the project proposals. As the number of R&D projects is growing relatively fast, it is 
likely that the supply of services lags behind the demand, depending on the growth strategies (i.e. loop B3) 
of the service providers. Lack of services is likely to have a negative impact on new project proposals of 
pharmaceutical companies as already discussed in 2.2.3.  
 
Figure 7: Support services 
Loop B3 describes how the supply and demand is balanced, i.e. how the support services react to the 
growing number of R&D projects. As the number of R&D projects increase, support services try to match 
this. The faster this loop operates, that is, the smaller the delay for service development is, the faster the 
service offering of the support service matches the demand of pharmaceutical R&D. Public investment can 
be used to enhance the growth of the support services and thus balance the supply and demand. This loop, 
if working slowly, can cause the supply to lag behind the demand, thus hindering the growth of the 
















































2.2.6 Academic research 
In this model, the main impact of academic research is through sample enriching (the same process as in 
pharmaceutical R&D projects), as research projects have to return the analysed data from the samples back 
to biobanks.  
 
Figure 8: Academic research 
3 Simulations 
In this chapter preliminary simulation results are presented. The simulation are targeted to gain 
understanding of the effects of public investments on various sectors of the ecosystem. 
The main interest of the simulations was to analyse the amount and evolution of biobank donors, samples 
and data, and pharmaceutical R&D as well as to study how the public investments (green parameters in the 
model) affect the evolvement of the ecosystem. In the model, public investments are focused to the 
following parts of the ecosystem in no particular order: 1) Sample genotyping, 2) Donor services, 3) Findata, 
4) Academic research, and 5) Support services:  
1. Investments to biobanks are considered from the perspective of genotyping of blood samples, 
which is mainly financed by research projects such as the ongoing Finngen5 project.  
2. Donor services are considered as a specific area, where targeted investments bring benefits for 
biobank donors with the objective of encouraging new individuals to contribute as donors.  
3. Investments to Findata are provided through the state budget and targeted to setting up the basic 
processes and information systems to handle data permit applications, connect data resources and 
to support secure processing of data.  
4. Investments to academic research refer to public funding of academic research projects (e.g. via 
the Academy of Finland) based on retrospective data resources.   
5. Investments to support services refer mainly to R&D funding (e.g. via Business Finland) to 
companies, which provide various services needed in exploiting data and sample resources. 
                                                          
5 FinnGen, https://www.finngen.fi/en/samples_come_from_biobanks 
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We have assumed that R&D of pharmaceutical companies do not receive direct public national funding but 
benefit indirectly from public investments directed to other stakeholders of the ecosystem. Also, the 
allocation of R&D funding for pharmaceutical companies is seen as an endogenous variable in the model.  
Thus any public investments (e.g. EU-project financing) for pharmaceutical R&D are considered to be 
included in the companies' total R&D budgets, and thus not explicitly modelled.  
The R&D activities are considered mainly from the point of view of pharmaceutical companies, as it is 
currently the main sector using biobank data. However, the model could be expanded to include also other 
emerging businesses utilizing health data.  
Table 1 contains parameter values for the scenarios presented. The first and second columns list the names 
and units of the decision parameters used in different scenarios. The second column (Base) in the table lists 
parameters reflecting a reference/baseline scenario. The rest of the columns (S0-S5) list parameters 
representing various alternative scenarios (mark ´-´ means the used value is the same as in Base scenario). 
If not otherwise indicated, the change is taking place at simulation time (t=0). The simulation start time is 
year -8, which represents year 2012. Thus, year 0 in the simulation represents year 2020 and year 20 year 
2040 respectively. 
Table 1: Simulation scenarios 
   
The initial simulation results are presented in sections 3.1 and 3.2. Total of seven simulations are 
presented. The first set of simulations concentrate on acquiring biobank consents by developing donor 
services. The second set of simulations present cases showing an optimistic and pessimistic scenarios. 
Scenarios are compared to baseline (Base) scenario. 
3.1 Base case, S00, S01, and S02 
Scenarios S00, S01, and S02 are presented in Figure 9, Figure 10, Figure 11, and Figure 12, showing the 
effect of two different donor service development rate (proportional yearly growth) and one scenario 
where people are withdrawing their consent (for some external reason, e.g. as a result of concerns to 
personal information security) and these are compared to baseline scenario. In scenario S00 the 
development of donor services is stopped at year 0. In scenario S01 donor services are developed double as 
fast as in baseline scenario. Scenario S02 presents an external biobank consent cancellation occurrence 
starting at year 5, lasting 3 years, and cancellations being 15% annually. For detailed description see Table 
1. 
Figure 9 presents the development status of donor services. The development status is described by a 
proportional value between 0 and 1. Maximum value (1) corresponds to the target situation where donor 
services are largely available for giving and managing biobank consents as well as for getting personal 
information about sample usage.    
Scenario parameters Unit Base S0 S1 S2 S3 S4 S5
Public investments in genotyping M€ 5 - - - 0 5 7
Public investment duration genotyping Year 3 - - - 0 10 20
Public investments in Findata M€ 3 - - - 0 6 8
Public investment duration Findata Year 5 - - - 0 6 6
Donor service development rate Dmnl 0,03 0 0,06 - 0 - 0,06
External biobank consent cancellation ratio M€ 0 - - 0,15 - - -
External biobank consent cancellation duration Year 0 - - 3 - - -
External biobank consent cancellation start time Year 0 - - 5 - - -
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Figure 10 presents the effect of donor service trajectories and consent cancellation on the development of 
biobank consents. The dynamics of biobank consent follow S-shaped growth curve as can be seen. The 
limiting factor is the amount of potential donors, which causes saturation as the probability of new 
consents decline when a major part of the population has already given the consent. The faster donor 
service development rate shown in scenario S01 causes faster consent accumulation, although the 
saturation causes the base scenario to catch up later. The lack of donor service development in scenario 
S00 causes the consents to saturate very fast. The consent cancellation scenario S02 causes a significant 
drop in consents and after that the growth trajectory is not as steep as in the base scenario (the consent 
cancellation has also an effect on the amount of potential donors, as it is easier not to give consent at all 
than to cancel it). 
  
Figure 9. Donor services. 
 
Figure 10. Biobank consents. 
  
Figure 11. All samples in biobanks. 
 
Figure 12. Genotyped data. 
 
Figure 11 presents the evolution of sample resources in biobanks. The amount of samples starts from zero, 
which describes the situation when the biobanks were not yet founded. When the biobanks were founded, 
a total of approximately 10 million samples (samples from 4 million persons6) were transferred to the 
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biobanks. After the initial sample dump the samples start to flow into the biobanks as consents are given, 
one sample per one consent. Also, when the consent has been given, samples accumulate slowly as 
additional biobank samples are taken from the donor in the context of healthcare services. Because of the 
initial dump of samples, the new samples collected together with new consents have a relatively small 
effect on the total amount of samples in biobanks. 
Figure 12 presents the accumulation of genotyped data. Genotyped data accumulation starts in the model 
roughly at time -2, after the biobanks have started collecting consents. In base scenario and scenarios S01-
S03 public funding for genotyping is stopped at year 3, after which enriching by R&D and academic projects 
is the only process producing genotyped data. In S00 the genotyping is stopped already before year 3, 
because of the slow development of consents all samples are already genotyped (not shown in the figures). 
For base scenario, S00, and S01 enriching has a significant effect on genotyped data in the long run, 
although it starts slowly. The effect of consent cancellation, S02, has also a significant effect on genotyped 
data, as it needs to be deleted after consent cancellation. 
3.2 Baseline, S03, S04, S05 
The following figures present the simulation results of four different scenarios: 1) Base: Baseline scenario, 
2) S03: no investments, 3) S04: moderate additional investments, and 4) S05: heavy additional investments. 
For detailed description see Table 1.  
Figure 13 presents the development of biobank consents (for more details see discussion related to Figure 
10 in section 3.1). Figure 14 presents the development of samples in biobanks (for more details see 
discussion related to Figure 11 in section 3.1). 
Figure 16 presents the accumulation of genotyped data and Figure 15 the samples available for genotyping. 
In scenario S03 funding for genotyping is stopped at year 0, so after that only enriching causes slow 
increase in genotyped data. In scenario S04 public funding for genotyping is continued until year 10. In 
scenario S05 increased funding for genotyping is continued for 20 years. However, after year 10 the 
genotyping drops because there is not enough new samples to be genotyped as can be seen in Figure 15. In 
this situation all new samples are proactively genotyped after taken from the donor.  
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Figure 13. Biobank consents. Figure 14. All samples in biobanks. 
 
Figure 15. Samples for genotyping. 
 
Figure 16. Genotyped data. 
 
Figure 17 and Figure 18 present the development of Findata and the related integration capability 
respectively. Both Findata progress and data integration capability are described by a proportional value 
between 0 and 1. For Findata, the maximum value (1) corresponds to the target level of services and 
capabilities where data is largely available via Findata services. For integration capability maximum value 
(1) means that data can be efficiently integrated from all health data registers for secondary use. 
Integration capability starts from 0.5, because already prior to Findata establishment integration has been 
possible to some extend.  
Figure 19 presents the value of data and sample resources perceived by the pharmaceutical companies and 
academic research community. Scenario S03 presents the effect of inadequate amount of genotyped data 
and poor integration capability combined. Base, S04, and S05 scenarios present the combination of 
increasing amount of genotyped data, samples, and integration capability, from which S05 results in highest 
value of data and samples. 
Figure 20 presents how the value of data and sample resources impact R&D project starts. This is also 
affected by other variables, but the value of data and sample resources has a significant effect. Base, S04, 
and S05 scenarios are converging towards each other the further the simulation runs, even though this 
effect is not seen in Error! Reference source not found.. This is because the effect of value of data and 
sample resources has saturated. The model assumes that with enough sample and data resources the 
additional resources will have a diminishing effect on the value of data, so at some point more data is not 
going to increase the value of data any more, thus the saturation. 
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Figure 17. Findata progress 
 
Figure 18. Data integration capability 
 
Figure 19. Value of data and samples for secondary use 
 
Figure 20. Pharmaceutical R&D project starts 
4 Discussion  
4.1 Model limitations  
As the ecosystem under study is extremely complicated it has been possible to include only selected 
aspects of it in the model. The ecosystem mechanisms are modelled by simplified approximations which 
still need further development. Short discussion on the main limitations is given below.  
An important limitation of the model is the link between sample and data resources and the 
pharmaceutical companies' decision to start a new R&D project exploiting data resources.  We do not know 
how companies value different types of data and sample resources and how large data and sample sets are 
needed. The different types of samples could be separately modelled. In the current model version, new 
samples have relatively small effect in increasing the existing sample resources of the biobanks (see Figure 
11). It may be required to model different sample types to get more realistic results, as the value of 
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types of pharmaceutical R&D projects where data can be exploited and the requirements concerning data 
and samples are highly variable. Further development of the model could include division between project 
types including, for example drug discovery, clinical trial support (subject identification and stratification), 
pharmacovigilance and impact assessment, as this may help to define the link between pharmaceutical 
R&D and perceived value of data.  
Modelling of the financial operation of biobanks has been omitted in the model. Such modelling would 
have required detailed information of the incomes and expenditures of biobanks, which has not been 
available for the project. Consequently, the effect of the service fees from R&D and academic projects to 
biobanks have not been included in the current model. In the future, these service fees are expected to 
have a growing effect on the biobank economy and to the accumulation of the sample and data resources.   
For the pharmaceutical companies and support services the availability of skilled personnel could become a 
bottleneck for future growth. Especially the lack of data analysts is seen potential hindrance to the 
ecosystem. This effect has been omitted from this version of the model. 
Academic research provides results with potential impact for new product development and related 
industry driven research projects.  National centers of excellence (Genome Center, National Cancer Center, 
Drug Development Centre, Neurocenter Finland) are expected to have a positive effect to initiation of 
industrial R&D projects based on academic research results. However, the current version of the model 
does not explicitly include the effect of academic research and the centers of excellence on industrial R&D 
projects.  The link between academic results (e.g. publications) and industrial R&D is not clear and its 
modelling requires further effort. The current model version still includes the effect of academic research 
on sample and data generation and the related indirect impact to R&D projects.   
More background information is being collected in order to improve the model structure and parameter 
values. 
4.2 Model validation 
Model validation has been an ongoing process throughout the model development. The structure of the 
model is based on expert knowledge as well as interview with different stakeholders of the ecosystem and 
the model has been exposed to feedback of different stakeholders. Also, we have used several of the 
standard model validation tests (Sterman, 2000). For example, we have used partial model testing to see 
how the model behaves when some parts of the model are removed (e.g. academic research and support 
services) and sensitivity analyses to study the sensitivity of the model with respect to different parameter 
values. We have also conducted out extreme condition tests to ensure realistic behaviour under different 
extreme conditions. 
Figure 21 and Figure 22 present biobank consents and the total number of research projects using biobank 
data. The data consists only a couple years of data, and thus the value of fitting the model to the data is 




Figure 21. Biobank consents. 
 
Figure 22. Total amount of biobank projects.  
 
4.3 Discussion on results  
The growth of the ecosystem is largely based on public investments that lead to increased amount of 
samples and data in biobanks. The simulation results indicate a favourable growth trend as long as public 
investments continue to support the accumulation of biobank consents, samples and data. Along with 
sample and data collection, Findata and the related infrastructure needed for integrating data is expected 
to have an important effect on the ecosystem. There are many internal and external aspects that can slow 
down the rapid development of the ecosystem and the public investment policy will have a remarkable 
impact on the growth trajectory of the business ecosystem, as can be seen from the preliminary simulation 
results presented in this paper. 
The services for biobank donors are still scarce. However, in line with the GDPR, register controllers would 
need to provide information for donors concerning the use of biobank samples and patient data. 
Consequently, there are currently ongoing initiatives towards setting up services for biobank donors, and 
new services are expected to gradually become available in 2021.   
5 Conclusions  
The paper describes a system dynamics model for data-driven precision medicine ecosystem, especially 
focusing on the analysis of biobank data and biosample accumulation and the related impact to 
pharmaceutical R&D projects. The model describes biobanks, pharmaceutical R&D projects, academic 
research, registry data access services (Findata) and R&D support services from the point of view of 
accumulation of data and sample resources. The main output and indicator of ecosystem growth is the 
number of initiated R&D projects with data exploitation as a key element.  The system dynamics model 
allows the simulation of various factors affecting the ecosystem growth. For example, the disturbance of 
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Preliminary simulation results are presented concerning the accumulation of biobank consents, samples, 
data, genotyped data as well as the evolution of Findata services, related capabilities for data integration 
and the initiation of pharmaceutical R&D projects.  While the accumulation of data and sample resources is 
always limited by the population, a significant improvement can be achieved by public investments. These 
are needed in provision of donor services, sample genotyping, and in building infrastructures for data 
access and integration (Findata services).  Large public-private precision medicine projects, such as the 
FinnGen project, are an important channel for focusing public funding to stimulate accumulation of sample 
and data resources.   
As the data-driven ecosystem is extremely complicated it has been possible to include only selected aspects 
of it in the model. The presented simulation results should be considered only indicative showing overall 
trends and dependencies. The model development activity continues with the objective of achieving a 
better coverage of the mechanisms affecting ecosystem growth. Further work is needed for example to 
take into account the differences between pharmaceutical R&D projects and their data exploitation needs. 
Also extension to R&D projects beyond the pharmaceutical industry is a potential target for further 
development. 
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